Zheng Y, et al. (2005) Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and Ras signaling systems in B cells. Blood 105, 3648-54 15657177

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T202-p - ERK1 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  lymphoma, Burkitt's lymphoma Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast) Cellular systems studied:  cell lines Species studied:  human, rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes anti-IgM increase Ro31-8220 anti-IgM inhibit treatment-induced increase Go_6976 anti-IgM inhibit treatment-induced increase phorbol_ester increase Ro31-8220 phorbol_ester inhibit treatment-induced increase Go_6976 phorbol_ester no effect upon treatment-induced increase anti-CD3 increase Ro31-8220 anti-CD3 inhibit treatment-induced increase Go_6976 anti-CD3 inhibit treatment-induced increase

Y204-p - ERK1 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  lymphoma, Burkitt's lymphoma Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast) Cellular systems studied:  cell lines Species studied:  human, rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes anti-IgM increase Ro31-8220 anti-IgM inhibit treatment-induced increase Go_6976 anti-IgM inhibit treatment-induced increase phorbol_ester increase Ro31-8220 phorbol_ester inhibit treatment-induced increase Go_6976 phorbol_ester no effect upon treatment-induced increase anti-CD3 increase Ro31-8220 anti-CD3 inhibit treatment-induced increase Go_6976 anti-CD3 inhibit treatment-induced increase

T185-p - ERK2 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  lymphoma, Burkitt's lymphoma Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast) Cellular systems studied:  cell lines Species studied:  human, rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes anti-IgM increase Ro31-8220 anti-IgM inhibit treatment-induced increase Go_6976 anti-IgM inhibit treatment-induced increase phorbol_ester increase Ro31-8220 phorbol_ester inhibit treatment-induced increase Go_6976 phorbol_ester no effect upon treatment-induced increase anti-CD3 increase Ro31-8220 anti-CD3 inhibit treatment-induced increase Go_6976 anti-CD3 inhibit treatment-induced increase

Y187-p - ERK2 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  lymphoma, Burkitt's lymphoma Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast) Cellular systems studied:  cell lines Species studied:  human, rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes anti-IgM increase Ro31-8220 anti-IgM inhibit treatment-induced increase Go_6976 anti-IgM inhibit treatment-induced increase phorbol_ester increase Ro31-8220 phorbol_ester inhibit treatment-induced increase Go_6976 phorbol_ester no effect upon treatment-induced increase anti-CD3 increase Ro31-8220 anti-CD3 inhibit treatment-induced increase Go_6976 anti-CD3 inhibit treatment-induced increase

T184-p - RASGRP1 (human) ▲

Modsite: RDWSRKLtQRIKSNT SwissProt Entrez-Gene Orthologous residues RASGRP1 (human): T184‑p, RASGRP1 (mouse): T184‑p, RASGRP1 (rat): T184‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), Rat2 (fibroblast) Cellular systems studied:  cell lines Species studied:  human, rat Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PKCT (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes anti-CD3 increase Ro31-8220 anti-CD3 inhibit treatment-induced increase Go_6976 anti-CD3 inhibit treatment-induced increase phorbol_ester increase

T133-p - RASGRP3 (human) ▲

Modsite: YDWMRRVtQRKKVSK SwissProt Entrez-Gene Orthologous residues RASGRP3 (human): T133‑p, RASGRP3 iso2 (human): T133‑p, RASGRP3 (mouse): T133‑p, RASGRP3 (rat): T133‑p, RASGRP3 (chicken): T133‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  lymphoma, Burkitt's lymphoma Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast) Cellular systems studied:  cell lines Species studied:  human, rat Enzymes shown to modify site in vitro:  Type Enzyme KINASE PKCD (human) KINASE PKCT (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PKCT (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes anti-IgM increase Ro31-8220 anti-IgM inhibit treatment-induced increase Go_6976 anti-IgM inhibit treatment-induced increase phorbol_ester increase Ro31-8220 phorbol_ester inhibit treatment-induced increase Go_6976 phorbol_ester no effect upon treatment-induced increase